Zydus Lifesciences announced the completion of enrolment for its Phase II clinical trial of Usnoflast (ZYIL1), an oral NLRP3 inflammasome inhibitor, in patients with Amyotrophic Lateral Sclerosis (ALS). In Europe, about 30,000 people are living with ALS, while India has an estimated 75,000 ALS patients. The Phase II clinical trial has enrolled 24 ALS patients across seven sites in India. Also read: Zydus Lifesciences gets USFDA nod for acne treatment gelThe company further informed they initiated a Phase II clinical study of Usnoflast in Ulcerative Colitis and established Phase II proof-of-concept in CAPS patients, with data published in Clinical Pharmacology in Drug Development. The USFDA has granted Usnoflast an ‘Orphan Drug Designation’ for the treatment of Cryopyrin Associated Periodic Syndrome (CAPS), a rare autoinflammatory disease.

Source: The Hindu May 25, 2024 03:33 UTC